Thymanax

RSS
Refused

This medicine has been refused authorisation

agomelatine
MedicineHumanRefused
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 27 July 2006 the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of a marketing authorisation for the medicinal product Valdoxan/Thymanax, 25 mg film-coated tablets intended for the treatment of major depressive disorder. The company that applied is Les Laboratoires Servier. The applicant requested a reexamination of the opinion, but withdrew this request before the CHMP completed the re-examination.

български (BG) (145.5 KB - PDF)

View

español (ES) (35.29 KB - PDF)

View

čeština (CS) (122.08 KB - PDF)

View

dansk (DA) (35.44 KB - PDF)

View

Deutsch (DE) (35.92 KB - PDF)

View

eesti keel (ET) (34.77 KB - PDF)

View

ελληνικά (EL) (141.23 KB - PDF)

View

français (FR) (35.35 KB - PDF)

View

italiano (IT) (35.5 KB - PDF)

View

latviešu valoda (LV) (144.01 KB - PDF)

View

lietuvių kalba (LT) (118.66 KB - PDF)

View

magyar (HU) (114.79 KB - PDF)

View

Nederlands (NL) (35.41 KB - PDF)

View

polski (PL) (126.21 KB - PDF)

View

português (PT) (35.39 KB - PDF)

View

română (RO) (135.39 KB - PDF)

View

slovenčina (SK) (118.24 KB - PDF)

View

slovenščina (SL) (112.72 KB - PDF)

View

Suomi (FI) (34.66 KB - PDF)

View

svenska (SV) (34.97 KB - PDF)

View

Product details

Name of medicine
Thymanax
Active substance
Agomelatine
International non-proprietary name (INN) or common name
agomelatine
Therapeutic area (MeSH)
Depressive Disorder, Major

Application details

EMA product number
EMEA/H/C/000657
Marketing authorisation applicant
Les Laboratoires Servier
Opinion adopted
27/07/2006
Refusal of marketing authorisation
16/01/2007

Assessment history

This page was last updated on

Share this page